Informed Prostate Cancer Patient Support

New Research Emphasizes Modifiable Risk Factors That May Slow or Prevent Disease Progression For the IPCSG Newsletter For men with prostate cancer on active surveillance (AS), the question of what they can actively do to prevent disease progression is paramount. Emerging research on cancer development and the role of lifestyle factors offers encouraging evidence that patients are not powerless—that modifiable behaviors may significantly influence whether low-risk prostate cancer remains indolent or progresses to require treatment. According to recent insights from Dr. Jason Fung, author of "The Cancer Code," and data from the American Cancer Society, approximately 40 percent of all cancers in the United States are associated with potentially modifiable risk factors, including obesity, poor diet, and physical inactivity. For men on active surveillance, this understanding shifts the focus from passive monitoring to active engagement in disease management through lifes...

New Research Emphasizes Modifiable Risk Factors That May Slow or Prevent Disease Progression For the IPCSG Newsletter For men with prostate cancer on active surveillance (AS), the question of what they can actively do to prevent disease progression is paramount. Emerging research on cancer development and the role of lifestyle factors offers encouraging evidence that patients are not powerless—that modifiable behaviors may significantly influence whether low-risk prostate cancer remains indolent or progresses to require treatment. According to recent insights from Dr. Jason Fung, author of "The Cancer Code," and data from the American Cancer Society, approximately 40 percent of all cancers in the United States are associated with potentially modifiable risk factors, including obesity, poor diet, and physical inactivity. For men on active surveillance, this understanding shifts the focus from passive monitoring to active engagement in disease management through lifestyle o...

  IPCSG Newsletter - September 2025 Editor's Note : Recent research has provided important insights into the side effects and safety profile of actinium-225 (²²⁵Ac) PSMA radioligand therapy. While this therapy shows promise for advanced prostate cancer, patients need to understand both its potential benefits and toxicities, including how it compares to emerging combination approaches. What is Actinium-225 PSMA Therapy? Actinium-225 PSMA radioligand therapy is an experimental targeted alpha therapy that uses radioactive particles to attack prostate cancer cells. Unlike lutetium-177 PSMA (which emits beta particles - high energy electrons), actinium-225 emits more powerful alpha particles (protons) that deliver greater cancer-killing energy while traveling shorter distances through tissue. Each decay produces four alpha particles, making it roughly 1000 times more powerful than beta radiation. Understanding the Decay Chain and Recoil Effect The Complex Decay Process...